Navigation Links
Minifold I Slot-Blot System, complete (Acrylic)

ProductsMinifold I Slot-Blot System, complete (Acrylic)
Company Whatman Inc.
Item Minifold I Slot-Blot System, complete (Acrylic)
Features Inquire
Description The Minifold I system consists of four basic components: sample well plate, filter support plate, vacuum plenum, and metal clamping plate (see diagram). The sample well plate is available in three configurations for producing spots, dots, or slots (see below). All three plates are interchangeable and can be purchased as an accessory plate in conjunction with a complete system. The tension on the clamping is adjustable, permitting use of a variety of blotting and filtration media.

Preferred format for densitometric scanning - slots can be easily quantitated.
Concentrated signal - 6 mm2 sample application area results in high signal intensity

Easy to survey format - 48 samples on your membrane are easier to view than 96 samples.

Specifications -
Material: Acrylic or Delrin
Filter Area: 6.24 mm2/slot (7.8x0.8mm)
Max Capacity: 1000 μl/well, 48 wells
Pressure: 0.9 bar, vacuum

Info Whatman Inc.
Customer Service: (800) WHATMAN
Web site: http://www.whatman.com/

Related medicine products :

1. Minifold I Dot-Blot System, complete (Acrylic)
2. Minifold I Dot-Blot System, complete (Delrin™)
3. Minifold I Spot-Blot System, complete (Acrylic)
4. Minifold I Dot-Blot System and incubation plate
5. Minifold II Slot-Blot System, complete
6. Proven Cruciate Retaining Knee System, standard
7. Proven Cruciate Retaining Knee System, curved
8. HemoCue 201 DM System, Hb
9. HemoCue 201 DM System, Glucose
10. Mini-TAG™ System, 2.0 mm
11. Mini-TAG™ System, 3.0 mm
Breaking Medicine Technology:Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy 2Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 2Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 4Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 5Frost 26amp 3B Sullivan Recognizes Fovia for its HDVR 28R 29 Platform A Disruptive Technology Breakthrough 6205 1Frost 26amp 3B Sullivan Recognizes Fovia for its HDVR 28R 29 Platform A Disruptive Technology Breakthrough 6205 2Frost 26amp 3B Sullivan Recognizes Fovia for its HDVR 28R 29 Platform A Disruptive Technology Breakthrough 6205 3Frost 26amp 3B Sullivan Recognizes Fovia for its HDVR 28R 29 Platform A Disruptive Technology Breakthrough 6205 4Colorado MRI Clinic Blends Ultra Patient Care with Significant Cost Savings 6201 1Colorado MRI Clinic Blends Ultra Patient Care with Significant Cost Savings 6201 2Colorado MRI Clinic Blends Ultra Patient Care with Significant Cost Savings 6201 3Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 1Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 2Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 3Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 4Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 5Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 6